Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | UBE2M | P61081 | 1/20 | 0.59 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | TACR3 | P29371 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 3/20 | 0.52 |
| ▸ | DRD2 | P14416 | 2/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | HTR2B | P41595 | 2/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16565554 | 0.89 | ACHE (0.56) | KMT2AMEN1SLC6A7EPHX2DRD4 | |
| SCHEMBL17886740 | 0.86 | ABL1 (0.67) | KMT2AMEN1HSD11B1MAPK7 | |
| SCHEMBL17888462 | 0.86 | PROKR1 (0.58) | KDM4EKMT2ANAMPT | |
| SCHEMBL14781405 | 0.80 | HSD11B1 (0.52) | KDM4EDRD4DRD2DRD3ADRA1D | |
| SCHEMBL17888407 | 0.79 | KDM4E (0.52) | KDM4EKMT2ASLC6A7TACR3 | |
| SCHEMBL4074303 | 0.79 | HSD11B1 (0.53) | DRD4DRD2DRD3ADRA1DADRA1A | |
| SCHEMBL19226493 | 0.79 | KDM4E (0.57) | KDM4EKMT2AMEN1SLC6A7EPHX2 | |
| SCHEMBL13212080 | 0.77 | PRMT5 (0.53) | KDM4EKMT2ASLC6A7TACR3HSD11B1 | |
| SCHEMBL19659044 | 0.77 | DRD4 (0.50) | EPHX2DRD4DRD2DRD3ADRA1D | |
| SCHEMBL19652164 | 0.77 | KDM5A (0.54) | DRD4DRD2DRD3ADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190233441-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-01 | — | — | US | disclosed |
| EP-3041841-B1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2019-06-05 | — | — | EP | disclosed |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | KDM4E 1708/4885UBE2M 4413/4885DCUN1D1 2793/4885 |
| US-20190233441-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | KDM4E 1708/4885UBE2M 4413/4885DCUN1D1 2793/4885 |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | KDM4E 1708/4885UBE2M 4413/4885DCUN1D1 2793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.